Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding

CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study

(2015) Anthony Shock et al.   ARTHRITIS RESEARCH & THERAPY

Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol

(2014) Gianfranco Pasut   BIODRUGS

GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety

(2014) R L O’Connor-Semmes et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Albumin and its application in drug delivery

(2014) Darrell Sleep   Expert Opinion on Drug Delivery

Interaction with Both Domain I and III of Albumin Is Required for Optimal pH-dependent Binding to the Neonatal Fc Receptor (FcRn)

(2014) Kine Marita Knudsen Sand et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding

(2014) Jan Terje Andersen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies

(2014) Yanguang Cao et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety

(2014) Patricia C. Ryan et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Albumin as a versatile platform for drug half-life extension

(2013) Darrell Sleep et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Binding of transition metal ions to albumin: Sites, affinities and rates

(2013) Wojciech Bal et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

A CHO cell line engineered to express XBP1 and ERO1-Lα has increased levels of transient protein expression

(2013) Katharine Cain et al.   BIOTECHNOLOGY PROGRESS

Single-chain Variable Fragment Albumin Fusions Bind the Neonatal Fc Receptor (FcRn) in a Species-dependent Manner

(2013) Jan Terje Andersen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The rapid generation of recombinant functional monoclonal antibodies from individual, antigen-specific bone marrow-derived plasma cells isolated using a novel fluorescence-based method

(2013) Alison M Clargo et al.   mAbs

PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins

(2013) M. Schlapschy et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Immunogenicity assays for antibody–drug conjugates: case study with ado-trastuzumab emtansine

(2013) Montserrat Carrasco-Triguero et al.   Bioanalysis

Extending the Serum Half-Life of G-CSF via Fusion with the Domain III of Human Serum Albumin

(2013) Shuqiang Zhao et al.   Biomed Research International

Fc-fusion proteins: new developments and future perspectives

(2012) Daniel M. Czajkowsky et al.   EMBO Molecular Medicine

Dual targeting strategies with bispecific antibodies

(2012) Roland Kontermann   mAbs

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

(2012) C. F. McDonagh et al.   MOLECULAR CANCER THERAPEUTICS

Stabilisation of the Fc Fragment of Human IgG1 by Engineered Intradomain Disulfide Bonds

(2012) Gordana Wozniak-Knopp et al.   PLoS One

Strategies for extended serum half-life of protein therapeutics

(2011) Roland E Kontermann   CURRENT OPINION IN BIOTECHNOLOGY

Plasma Half-life Extension of Small Recombinant Antibodies by Fusion to Immunoglobulin-binding Domains

(2011) Meike Hutt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Impact of albumin on drug delivery — New applications on the horizon

(2011) Bakheet Elsadek et al.   JOURNAL OF CONTROLLED RELEASE

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

(2011) Rong Deng et al.   mAbs

Elastin-like polypeptides: Biomedical applications of tunable biopolymers

(2010) Sarah R. MacEwan et al.   BIOPOLYMERS

PEGylation of therapeutic proteins

(2010) Simona Jevševar et al.   Biotechnology Journal

Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain

(2010) Jan Terje Andersen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice

(2010) L. Robles-Carrillo et al.   JOURNAL OF IMMUNOLOGY

Antibody fragments

(2010) Aaron L. Nelson   mAbs

Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins

(2010) V. E. Kenanova et al.   PROTEIN ENGINEERING DESIGN & SELECTION

The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein

(2010) J. Hopp et al.   PROTEIN ENGINEERING DESIGN & SELECTION

The production, characterisation and enhanced pharmacokinetics of scFv–albumin fusions expressed in Saccharomyces cerevisiae

(2010) Leslie Evans et al.   PROTEIN EXPRESSION AND PURIFICATION

A multiple-dose toxicity study of tanezumab in cynomolgus monkeys

(2010) Mark Zorbas et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

New Strategy for the Extension of the Serum Half-Life of Antibody Fragments

(2009) Sabrina Trüssel et al.   BIOCONJUGATE CHEMISTRY

Strategies to Extend Plasma Half-Lives of Recombinant Antibodies

(2009) Roland E. Kontermann   BIODRUGS

Therapeutic antibodies: successes, limitations and hopes for the future

(2009) Patrick Chames et al.   BRITISH JOURNAL OF PHARMACOLOGY

Relevant shaking stress conditions for antibody preformulation development

(2009) Annette Eppler et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Design and optimization of a linker for fusion protein construction

(2009) Jianhua Zhang et al.   Progress in Natural Science-Materials International

A modular IgG-scFv bispecific antibody topology

(2009) Kelly Davis Orcutt et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies

(2009) Rafael Ponce et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

(2008) B. M. Tijink et al.   MOLECULAR CANCER THERAPEUTICS

Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs

(2008) L. J. Holt et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Structural and Thermodynamic Approach to Peptide Immunogenicity

(2008) Carlos J. Camacho et al.   PLoS Computational Biology